Valsartan Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Product Type
Description
Valsartan Market Summary
The valsartan market focuses on the production and distribution of valsartan, a widely used angiotensin II receptor blocker (ARB) primarily prescribed for the treatment of hypertension, heart failure, and post-myocardial infarction care. As the most consumed ARB globally, valsartan is critical in managing cardiovascular conditions, driven by the rising prevalence of hypertension, which affects over 1.5 billion people worldwide according to global health estimates. valsartans, available as tablets and capsules, offer effective blood pressure control with a favorable safety profile, making them a cornerstone of cardiovascular therapy. The market is characterized by a high degree of regulatory scrutiny due to the pharmaceutical nature of the product, requiring compliance with stringent quality standards such as Good Manufacturing Practices (GMP). Key players like Zhejiang Tianyu and Zhejiang Huahai dominate the supply of valsartan active pharmaceutical ingredients (APIs), supporting the global production of formulations. However, the market has faced significant challenges due to quality issues, notably the 2018 recall of valsartan products from Zhejiang Huahai in multiple countries, including China, Germany, Italy, Finland, Austria, and Japan, after the detection of N-nitrosodimethylamine (NDMA), a carcinogenic impurity. Additionally, in April 2021, the European Directorate for the Quality of Medicines & HealthCare (EDQM) identified mutagenic azide impurities in some ARB APIs, leading to further recalls of valsartan, irbesartan, and losartan by Health Canada in May 2021. These incidents have heightened regulatory oversight and driven demand for high-purity APIs and robust quality control in formulations. Emerging trends include the growth of generic valsartans due to patent expirations, increasing adoption in emerging markets, and innovations in impurity-free manufacturing processes.
Market Size and Growth Forecast
The global valsartan market is projected to reach USD 3–4 billion by 2025, with an estimated compound annual growth rate (CAGR) of 2%–4% through 2030. Growth is driven by the rising global burden of hypertension, increasing demand for affordable generics, and expanding healthcare access in developing regions, though tempered by regulatory challenges and market saturation in developed regions.
Regional Analysis
Asia Pacific is expected to lead the valsartan market with a growth rate of 3%–5%, driven by China and India. China, a major hub for valsartan API production, benefits from its large pharmaceutical manufacturing base and growing domestic demand for cardiovascular treatments, fueled by an aging population and rising lifestyle-related diseases. India’s robust generic drug industry supports strong demand for cost-effective valsartans, with companies like Aurobindo Pharma and Lupin Pharmaceuticals catering to both domestic and export markets. Japan also contributes to regional growth, with a focus on high-quality formulations for its aging population.
North America follows with a growth rate of 2%–4%, led by the United States, where hypertension affects over 100 million adults. The region’s demand for valsartan is driven by its widespread use in cardiovascular care, though recalls due to impurities have increased scrutiny and demand for high-quality generics. Canada’s market is similarly influenced by regulatory actions, such as the 2021 recalls, which have pushed manufacturers to prioritize impurity-free production.
Europe, with a growth rate of 2%–3.5%, is driven by countries like Germany, the UK, and France, where cardiovascular diseases remain a leading health concern. The region’s stringent regulatory environment, exemplified by the EDQM’s 2021 impurity findings, has accelerated the adoption of advanced quality control measures, supporting demand for trusted formulations from companies like Novartis.
South America, with a growth rate of 1.5%–3%, sees demand in Brazil and Argentina, driven by improving healthcare infrastructure and rising awareness of hypertension management. Economic constraints, however, limit broader market penetration. The Middle East and Africa, with a growth rate of 1.5%–2.5%, show potential in countries like South Africa and Saudi Arabia, where healthcare investments are increasing, though access to advanced treatments remains limited by economic disparities.
Type Analysis
Tablets: Expected to grow at 2%–4%, tablets dominate the valsartan market due to their ease of administration, precise dosing, and widespread use in hypertension and heart failure treatment. Tablets are favored for their cost-effectiveness and suitability for mass production, particularly in the generic market. Trends include the development of fixed-dose combination tablets with other antihypertensives, such as hydrochlorothiazide, to enhance efficacy and patient compliance.
Capsules: Projected to grow at 1.5%–3.5%, capsules are less common but valued for specific patient populations requiring alternative formulations, such as those with swallowing difficulties. Capsules also allow for innovative delivery systems, such as extended-release formulations. Trends include increasing adoption in niche markets and efforts to improve capsule stability to meet stringent regulatory standards.
Key Market Players
Novartis: A Swiss-based global pharmaceutical leader, Novartis produces valsartans under its brand Diovan, focusing on high-quality cardiovascular treatments for global markets, with a strong presence in Europe and North America.
Mylan: A U.S.-based company, Mylan offers generic valsartans, emphasizing affordability and accessibility for hypertension management, with a significant market share in North America and Europe.
Aurobindo Pharma: An Indian pharmaceutical company, Aurobindo produces cost-effective valsartan tablets and capsules, serving both domestic and international markets with a focus on generic drug expansion.
Lupin Pharmaceuticals: Based in India, Lupin manufactures valsartans for cardiovascular treatments, leveraging its strong R&D capabilities to meet global regulatory standards and supply emerging markets.
Alembic Pharmaceuticals: An Indian firm, Alembic focuses on affordable valsartans, particularly tablets, catering to the growing demand for generics in Asia and Africa.
Zhejiang Tianyu: A Chinese API and formulation manufacturer, Zhejiang Tianyu is a key supplier of valsartan, producing high-quality formulations for domestic and export markets, with a focus on regulatory compliance.
Zhejiang Huahai: Another major Chinese player, Zhejiang Huahai produces valsartan APIs and formulations, though its reputation was impacted by the 2018 NDMA recall. The company now emphasizes advanced quality control.
Changzhou Siyao: A Chinese pharmaceutical company, Changzhou Siyao manufactures valsartans, focusing on cost-effective production for China’s growing healthcare market.
Le Pu Hengyuan: Based in China, Le Pu Hengyuan produces valsartans, targeting domestic demand for cardiovascular drugs with an emphasis on scalability and affordability.
Livzon Pharmaceutical: A Chinese firm, Livzon manufactures valsartans, focusing on high-quality production to meet both domestic and international regulatory standards.
Tianda Pharmaceuticals: Operating in China, Tianda produces valsartan tablets and capsules, serving the domestic market and expanding into Asia Pacific with affordable generics.
Aomei Pharmaceutical: A Chinese manufacturer, Aomei focuses on valsartans for hypertension treatment, emphasizing cost-competitive solutions for emerging markets.
Yung Shin Pharm: Based in Taiwan, Yung Shin manufactures valsartans, targeting Asia Pacific markets with high-quality generics and a focus on regulatory compliance.
Lunan Pharmaceutical: A Chinese company, Lunan produces valsartans, leveraging its large production capacity to meet domestic and regional demand for cardiovascular drugs.
Hainan Hualon: Operating in China, Hainan Hualon manufactures valsartans, focusing on affordability and accessibility for China’s growing healthcare sector.
Guilin Winsun: A Chinese pharmaceutical firm, Guilin Winsun produces valsartans, targeting cost-sensitive markets in Asia with a focus on generic drugs.
Medisan: Based in China, Medisan manufactures valsartans, emphasizing quality and scalability to serve both domestic and export markets.
Harman Finochem Pvt Ltd: An Indian company, Harman Finochem produces valsartan APIs and formulations, focusing on high-quality generics for global pharmaceutical markets.
Porter’s Five Forces Analysis
Threat of New Entrants: Moderate. The valsartan market has significant barriers to entry, including high capital costs for GMP-compliant facilities, stringent regulatory requirements, and the need for advanced chemical expertise. Established players like Novartis and Aurobindo benefit from economies of scale, but new entrants in Asia, particularly China and India, are increasing competition with cost-competitive generics.
Threat of Substitutes: Moderate. Alternative ARBs, such as losartan and irbesartan, and other antihypertensive classes like ACE inhibitors compete with valsartan. However, valsartan’s established efficacy, widespread use in generics, and inclusion in combination therapies limit substitution, though newer drugs with fewer side effects pose a threat.
Bargaining Power of Buyers: High. Pharmaceutical distributors, hospitals, and pharmacies have significant negotiating power due to the availability of multiple valsartan suppliers, particularly generics from India and China. However, brand loyalty to products like Novartis’ Diovan and regulatory requirements for quality limit switching in premium markets.
Bargaining Power of Suppliers: Moderate. Suppliers of valsartan APIs, such as Zhejiang Tianyu and Zhejiang Huahai, hold some leverage due to concentrated supply chains. However, vertical integration by formulation manufacturers and the availability of alternative API suppliers balance this power.
Competitive Rivalry: High. The market is highly competitive, with global players like Novartis and generics manufacturers like Mylan and Lupin competing on price, quality, and regulatory compliance. The focus on impurity-free production and cost-effective generics, particularly in Asia, intensifies rivalry, as companies invest in R&D to address quality concerns.
Market Opportunities and Challenges
Opportunities
Rising Hypertension Prevalence: The global burden of hypertension, affecting over 1.5 billion people, drives demand for valsartans, particularly in affordable generic forms in emerging markets.
Generic Drug Expansion: Patent expirations and increasing demand for cost-effective medications in Asia, Africa, and South America create opportunities for generic valsartans.
Healthcare Infrastructure Growth: Investments in healthcare access in Asia Pacific and South America increase the availability of valsartan-based treatments for cardiovascular conditions.
Quality Control Innovations: Advances in impurity-free manufacturing processes, driven by regulatory scrutiny, offer opportunities for manufacturers to differentiate their products and regain consumer trust.
Emerging Market Penetration: Rapid urbanization and rising disposable incomes in countries like India and Brazil create demand for accessible, high-quality valsartans.
Challenges
Regulatory Scrutiny: Recalls due to NDMA and azide impurities, coupled with stringent regulations in Europe and North America, increase compliance costs and delay market entry.
Quality Control Costs: Ensuring impurity-free production requires significant investment in advanced manufacturing and testing, limiting affordability in price-sensitive markets.
Supply Chain Risks: Dependency on specialized API suppliers exposes the market to risks, including geopolitical disruptions and raw material shortages.
Competition from Alternatives: The availability of other ARBs and antihypertensive drugs pressures valsartan’s market share, particularly in developed markets with access to newer therapies.
Patent and Pricing Pressures: Intense competition in the generics market, particularly in Asia, drives price erosion, challenging profitability for smaller manufacturers.
The valsartan market focuses on the production and distribution of valsartan, a widely used angiotensin II receptor blocker (ARB) primarily prescribed for the treatment of hypertension, heart failure, and post-myocardial infarction care. As the most consumed ARB globally, valsartan is critical in managing cardiovascular conditions, driven by the rising prevalence of hypertension, which affects over 1.5 billion people worldwide according to global health estimates. valsartans, available as tablets and capsules, offer effective blood pressure control with a favorable safety profile, making them a cornerstone of cardiovascular therapy. The market is characterized by a high degree of regulatory scrutiny due to the pharmaceutical nature of the product, requiring compliance with stringent quality standards such as Good Manufacturing Practices (GMP). Key players like Zhejiang Tianyu and Zhejiang Huahai dominate the supply of valsartan active pharmaceutical ingredients (APIs), supporting the global production of formulations. However, the market has faced significant challenges due to quality issues, notably the 2018 recall of valsartan products from Zhejiang Huahai in multiple countries, including China, Germany, Italy, Finland, Austria, and Japan, after the detection of N-nitrosodimethylamine (NDMA), a carcinogenic impurity. Additionally, in April 2021, the European Directorate for the Quality of Medicines & HealthCare (EDQM) identified mutagenic azide impurities in some ARB APIs, leading to further recalls of valsartan, irbesartan, and losartan by Health Canada in May 2021. These incidents have heightened regulatory oversight and driven demand for high-purity APIs and robust quality control in formulations. Emerging trends include the growth of generic valsartans due to patent expirations, increasing adoption in emerging markets, and innovations in impurity-free manufacturing processes.
Market Size and Growth Forecast
The global valsartan market is projected to reach USD 3–4 billion by 2025, with an estimated compound annual growth rate (CAGR) of 2%–4% through 2030. Growth is driven by the rising global burden of hypertension, increasing demand for affordable generics, and expanding healthcare access in developing regions, though tempered by regulatory challenges and market saturation in developed regions.
Regional Analysis
Asia Pacific is expected to lead the valsartan market with a growth rate of 3%–5%, driven by China and India. China, a major hub for valsartan API production, benefits from its large pharmaceutical manufacturing base and growing domestic demand for cardiovascular treatments, fueled by an aging population and rising lifestyle-related diseases. India’s robust generic drug industry supports strong demand for cost-effective valsartans, with companies like Aurobindo Pharma and Lupin Pharmaceuticals catering to both domestic and export markets. Japan also contributes to regional growth, with a focus on high-quality formulations for its aging population.
North America follows with a growth rate of 2%–4%, led by the United States, where hypertension affects over 100 million adults. The region’s demand for valsartan is driven by its widespread use in cardiovascular care, though recalls due to impurities have increased scrutiny and demand for high-quality generics. Canada’s market is similarly influenced by regulatory actions, such as the 2021 recalls, which have pushed manufacturers to prioritize impurity-free production.
Europe, with a growth rate of 2%–3.5%, is driven by countries like Germany, the UK, and France, where cardiovascular diseases remain a leading health concern. The region’s stringent regulatory environment, exemplified by the EDQM’s 2021 impurity findings, has accelerated the adoption of advanced quality control measures, supporting demand for trusted formulations from companies like Novartis.
South America, with a growth rate of 1.5%–3%, sees demand in Brazil and Argentina, driven by improving healthcare infrastructure and rising awareness of hypertension management. Economic constraints, however, limit broader market penetration. The Middle East and Africa, with a growth rate of 1.5%–2.5%, show potential in countries like South Africa and Saudi Arabia, where healthcare investments are increasing, though access to advanced treatments remains limited by economic disparities.
Type Analysis
Tablets: Expected to grow at 2%–4%, tablets dominate the valsartan market due to their ease of administration, precise dosing, and widespread use in hypertension and heart failure treatment. Tablets are favored for their cost-effectiveness and suitability for mass production, particularly in the generic market. Trends include the development of fixed-dose combination tablets with other antihypertensives, such as hydrochlorothiazide, to enhance efficacy and patient compliance.
Capsules: Projected to grow at 1.5%–3.5%, capsules are less common but valued for specific patient populations requiring alternative formulations, such as those with swallowing difficulties. Capsules also allow for innovative delivery systems, such as extended-release formulations. Trends include increasing adoption in niche markets and efforts to improve capsule stability to meet stringent regulatory standards.
Key Market Players
Novartis: A Swiss-based global pharmaceutical leader, Novartis produces valsartans under its brand Diovan, focusing on high-quality cardiovascular treatments for global markets, with a strong presence in Europe and North America.
Mylan: A U.S.-based company, Mylan offers generic valsartans, emphasizing affordability and accessibility for hypertension management, with a significant market share in North America and Europe.
Aurobindo Pharma: An Indian pharmaceutical company, Aurobindo produces cost-effective valsartan tablets and capsules, serving both domestic and international markets with a focus on generic drug expansion.
Lupin Pharmaceuticals: Based in India, Lupin manufactures valsartans for cardiovascular treatments, leveraging its strong R&D capabilities to meet global regulatory standards and supply emerging markets.
Alembic Pharmaceuticals: An Indian firm, Alembic focuses on affordable valsartans, particularly tablets, catering to the growing demand for generics in Asia and Africa.
Zhejiang Tianyu: A Chinese API and formulation manufacturer, Zhejiang Tianyu is a key supplier of valsartan, producing high-quality formulations for domestic and export markets, with a focus on regulatory compliance.
Zhejiang Huahai: Another major Chinese player, Zhejiang Huahai produces valsartan APIs and formulations, though its reputation was impacted by the 2018 NDMA recall. The company now emphasizes advanced quality control.
Changzhou Siyao: A Chinese pharmaceutical company, Changzhou Siyao manufactures valsartans, focusing on cost-effective production for China’s growing healthcare market.
Le Pu Hengyuan: Based in China, Le Pu Hengyuan produces valsartans, targeting domestic demand for cardiovascular drugs with an emphasis on scalability and affordability.
Livzon Pharmaceutical: A Chinese firm, Livzon manufactures valsartans, focusing on high-quality production to meet both domestic and international regulatory standards.
Tianda Pharmaceuticals: Operating in China, Tianda produces valsartan tablets and capsules, serving the domestic market and expanding into Asia Pacific with affordable generics.
Aomei Pharmaceutical: A Chinese manufacturer, Aomei focuses on valsartans for hypertension treatment, emphasizing cost-competitive solutions for emerging markets.
Yung Shin Pharm: Based in Taiwan, Yung Shin manufactures valsartans, targeting Asia Pacific markets with high-quality generics and a focus on regulatory compliance.
Lunan Pharmaceutical: A Chinese company, Lunan produces valsartans, leveraging its large production capacity to meet domestic and regional demand for cardiovascular drugs.
Hainan Hualon: Operating in China, Hainan Hualon manufactures valsartans, focusing on affordability and accessibility for China’s growing healthcare sector.
Guilin Winsun: A Chinese pharmaceutical firm, Guilin Winsun produces valsartans, targeting cost-sensitive markets in Asia with a focus on generic drugs.
Medisan: Based in China, Medisan manufactures valsartans, emphasizing quality and scalability to serve both domestic and export markets.
Harman Finochem Pvt Ltd: An Indian company, Harman Finochem produces valsartan APIs and formulations, focusing on high-quality generics for global pharmaceutical markets.
Porter’s Five Forces Analysis
Threat of New Entrants: Moderate. The valsartan market has significant barriers to entry, including high capital costs for GMP-compliant facilities, stringent regulatory requirements, and the need for advanced chemical expertise. Established players like Novartis and Aurobindo benefit from economies of scale, but new entrants in Asia, particularly China and India, are increasing competition with cost-competitive generics.
Threat of Substitutes: Moderate. Alternative ARBs, such as losartan and irbesartan, and other antihypertensive classes like ACE inhibitors compete with valsartan. However, valsartan’s established efficacy, widespread use in generics, and inclusion in combination therapies limit substitution, though newer drugs with fewer side effects pose a threat.
Bargaining Power of Buyers: High. Pharmaceutical distributors, hospitals, and pharmacies have significant negotiating power due to the availability of multiple valsartan suppliers, particularly generics from India and China. However, brand loyalty to products like Novartis’ Diovan and regulatory requirements for quality limit switching in premium markets.
Bargaining Power of Suppliers: Moderate. Suppliers of valsartan APIs, such as Zhejiang Tianyu and Zhejiang Huahai, hold some leverage due to concentrated supply chains. However, vertical integration by formulation manufacturers and the availability of alternative API suppliers balance this power.
Competitive Rivalry: High. The market is highly competitive, with global players like Novartis and generics manufacturers like Mylan and Lupin competing on price, quality, and regulatory compliance. The focus on impurity-free production and cost-effective generics, particularly in Asia, intensifies rivalry, as companies invest in R&D to address quality concerns.
Market Opportunities and Challenges
Opportunities
Rising Hypertension Prevalence: The global burden of hypertension, affecting over 1.5 billion people, drives demand for valsartans, particularly in affordable generic forms in emerging markets.
Generic Drug Expansion: Patent expirations and increasing demand for cost-effective medications in Asia, Africa, and South America create opportunities for generic valsartans.
Healthcare Infrastructure Growth: Investments in healthcare access in Asia Pacific and South America increase the availability of valsartan-based treatments for cardiovascular conditions.
Quality Control Innovations: Advances in impurity-free manufacturing processes, driven by regulatory scrutiny, offer opportunities for manufacturers to differentiate their products and regain consumer trust.
Emerging Market Penetration: Rapid urbanization and rising disposable incomes in countries like India and Brazil create demand for accessible, high-quality valsartans.
Challenges
Regulatory Scrutiny: Recalls due to NDMA and azide impurities, coupled with stringent regulations in Europe and North America, increase compliance costs and delay market entry.
Quality Control Costs: Ensuring impurity-free production requires significant investment in advanced manufacturing and testing, limiting affordability in price-sensitive markets.
Supply Chain Risks: Dependency on specialized API suppliers exposes the market to risks, including geopolitical disruptions and raw material shortages.
Competition from Alternatives: The availability of other ARBs and antihypertensive drugs pressures valsartan’s market share, particularly in developed markets with access to newer therapies.
Patent and Pricing Pressures: Intense competition in the generics market, particularly in Asia, drives price erosion, challenging profitability for smaller manufacturers.
Table of Contents
105 Pages
- Chapter 1 Executive Summary
- Chapter 2 Abbreviation and Acronyms
- Chapter 3 Preface
- 3.1 Research Scope
- 3.2 Research Sources
- 3.2.1 Data Sources
- 3.2.2 Assumptions
- 3.3 Research Method
- Chapter 4 Market Landscape
- 4.1 Market Overview
- 4.2 Classification/Types
- 4.3 Application/End Users
- Chapter 5 Market Trend Analysis
- 5.1 Introduction
- 5.2 Drivers
- 5.3 Restraints
- 5.4 Opportunities
- 5.5 Threats
- Chapter 6 Industry Chain Analysis
- 6.1 Upstream/Suppliers Analysis
- 6.2 Valsartan Analysis
- 6.2.1 Technology Analysis
- 6.2.2 Cost Analysis
- 6.2.3 Market Channel Analysis
- 6.3 Downstream Buyers/End Users
- Chapter 7 Latest Market Dynamics
- 7.1 Latest News
- 7.2 Merger and Acquisition
- 7.3 Planned/Future Project
- 7.4 Policy Dynamics
- Chapter 8 Trading Analysis
- 8.1 Export of Valsartan by Region
- 8.2 Import of Valsartan by Region
- 8.3 Balance of Trade
- Chapter 9 Historical and Forecast Valsartan Market in North America (2020-2030)
- 9.1 Valsartan Market Size
- 9.2 Valsartan Demand by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Type Segmentation and Price
- 9.5 Key Countries Analysis
- 9.5.1 United States
- 9.5.2 Canada
- 9.5.3 Mexico
- Chapter 10 Historical and Forecast Valsartan Market in South America (2020-2030)
- 10.1 Valsartan Market Size
- 10.2 Valsartan Demand by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Type Segmentation and Price
- 10.5 Key Countries Analysis
- 10.5.1 Brazil
- 10.5.2 Argentina
- 10.5.3 Chile
- 10.5.4 Peru
- Chapter 11 Historical and Forecast Valsartan Market in Asia & Pacific (2020-2030)
- 11.1 Valsartan Market Size
- 11.2 Valsartan Demand by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Type Segmentation and Price
- 11.5 Key Countries Analysis
- 11.5.1 China
- 11.5.2 India
- 11.5.3 Japan
- 11.5.4 South Korea
- 11.5.5 Southest Asia
- 11.5.6 Australia
- Chapter 12 Historical and Forecast Valsartan Market in Europe (2020-2030)
- 12.1 Valsartan Market Size
- 12.2 Valsartan Demand by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Type Segmentation and Price
- 12.5 Key Countries Analysis
- 12.5.1 Germany
- 12.5.2 France
- 12.5.3 United Kingdom
- 12.5.4 Italy
- 12.5.5 Spain
- 12.5.6 Belgium
- 12.5.7 Netherlands
- 12.5.8 Austria
- 12.5.9 Poland
- 12.5.10 Russia
- Chapter 13 Historical and Forecast Valsartan Market in MEA (2020-2030)
- 13.1 Valsartan Market Size
- 13.2 Valsartan Demand by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Type Segmentation and Price
- 13.5 Key Countries Analysis
- 13.5.1 Egypt
- 13.5.2 Israel
- 13.5.3 South Africa
- 13.5.4 Gulf Cooperation Council Countries
- 13.5.5 Turkey
- Chapter 14 Summary For Global Valsartan Market (2020-2025)
- 14.1 Valsartan Market Size
- 14.2 Valsartan Demand by End Use
- 14.3 Competition by Players/Suppliers
- 14.4 Type Segmentation and Price
- Chapter 15 Global Valsartan Market Forecast (2025-2030)
- 15.1 Valsartan Market Size Forecast
- 15.2 Valsartan Demand Forecast
- 15.3 Competition by Players/Suppliers
- 15.4 Type Segmentation and Price Forecast
- Chapter 16 Analysis of Global Key Vendors
- 16.1 Novartis
- 16.1.1 Company Profile
- 16.1.2 Main Business and Valsartan Information
- 16.1.3 SWOT Analysis of Novartis
- 16.1.4 Novartis Valsartan Sales, Revenue, Price and Gross Margin (2020-2025)
- 16.2 Mylan
- 16.2.1 Company Profile
- 16.2.2 Main Business and Valsartan Information
- 16.2.3 SWOT Analysis of Mylan
- 16.2.4 Mylan Valsartan Sales, Revenue, Price and Gross Margin (2020-2025)
- 16.3 Aurobindo Pharma
- 16.3.1 Company Profile
- 16.3.2 Main Business and Valsartan Information
- 16.3.3 SWOT Analysis of Aurobindo Pharma
- 16.3.4 Aurobindo Pharma Valsartan Sales, Revenue, Price and Gross Margin (2020-2025)
- 16.4 Lupin Pharmaceuticals
- 16.4.1 Company Profile
- 16.4.2 Main Business and Valsartan Information
- 16.4.3 SWOT Analysis of Lupin Pharmaceuticals
- 16.4.4 Lupin Pharmaceuticals Valsartan Sales, Revenue, Price and Gross Margin (2020-2025)
- 16.5 Alembic Pharmaceuticals
- 16.5.1 Company Profile
- 16.5.2 Main Business and Valsartan Information
- 16.5.3 SWOT Analysis of Alembic Pharmaceuticals
- 16.5.4 Alembic Pharmaceuticals Valsartan Sales, Revenue, Price and Gross Margin (2020-2025)
- 16.6 Zhejiang Tianyu
- 16.6.1 Company Profile
- 16.6.2 Main Business and Valsartan Information
- 16.6.3 SWOT Analysis of Zhejiang Tianyu
- 16.6.4 Zhejiang Tianyu Valsartan Sales, Revenue, Price and Gross Margin (2020-2025)
- 16.7 Zhejiang Huahai
- 16.7.1 Company Profile
- 16.7.2 Main Business and Valsartan Information
- 16.7.3 SWOT Analysis of Zhejiang Huahai
- 16.7.4 Zhejiang Huahai Valsartan Sales, Revenue, Price and Gross Margin (2020-2025)
- 16.8 Changzhou Siyao
- 16.8.1 Company Profile
- 16.8.2 Main Business and Valsartan Information
- 16.8.3 SWOT Analysis of Changzhou Siyao
- 16.8.4 Changzhou Siyao Valsartan Sales, Revenue, Price and Gross Margin (2020-2025)
- 16.9 Le Pu Hengyuan
- 16.9.1 Company Profile
- 16.9.2 Main Business and Valsartan Information
- 16.9.3 SWOT Analysis of Le Pu Hengyuan
- 16.9.4 Le Pu Hengyuan Valsartan Sales, Revenue, Price and Gross Margin (2020-2025)
- 16.10 Livzon Pharmaceutical
- 16.10.1 Company Profile
- 16.10.2 Main Business and Valsartan Information
- 16.10.3 SWOT Analysis of Livzon Pharmaceutical
- 16.10.4 Livzon Pharmaceutical Valsartan Sales, Revenue, Price and Gross Margin (2020-2025)
- 16.11 Tianda Pharmaceuticals
- 16.11.1 Company Profile
- 16.11.2 Main Business and Valsartan Information
- 16.11.3 SWOT Analysis of Tianda Pharmaceuticals
- 16.11.4 Tianda Pharmaceuticals Valsartan Sales, Revenue, Price and Gross Margin (2020-2025)
- 16.12 Aomei Pharmaceutical
- 16.12.1 Company Profile
- 16.12.2 Main Business and Valsartan Information
- 16.12.3 SWOT Analysis of Aomei Pharmaceutical
- 16.12.4 Aomei Pharmaceutical Valsartan Sales, Revenue, Price and Gross Margin (2020-2025)
- 16.13 Yung Shin Pharm
- 16.13.1 Company Profile
- 16.13.2 Main Business and Valsartan Information
- 16.13.3 SWOT Analysis of Yung Shin Pharm
- 16.13.4 Yung Shin Pharm Valsartan Sales, Revenue, Price and Gross Margin (2020-2025)
- Please ask for sample pages for full companies list
- Tables and Figures
- Table Abbreviation and Acronyms List
- Table Research Scope of Valsartan Report
- Table Data Sources of Valsartan Report
- Table Major Assumptions of Valsartan Report
- Figure Market Size Estimated Method
- Figure Major Forecasting Factors
- Figure Valsartan Picture
- Table Valsartan Classification
- Table Valsartan Applications List
- Table Drivers of Valsartan Market
- Table Restraints of Valsartan Market
- Table Opportunities of Valsartan Market
- Table Threats of Valsartan Market
- Table Covid-19 Impact For Valsartan Market
- Table Raw Materials Suppliers List
- Table Different Production Methods of Valsartan
- Table Cost Structure Analysis of Valsartan
- Table Key End Users List
- Table Latest News of Valsartan Market
- Table Merger and Acquisition List
- Table Planned/Future Project of Valsartan Market
- Table Policy of Valsartan Market
- Table 2020-2030 Regional Export of Valsartan
- Table 2020-2030 Regional Import of Valsartan
- Table 2020-2030 Regional Trade Balance
- Figure 2020-2030 Regional Trade Balance
- Table 2020-2030 North America Valsartan Market Size and Market Volume List
- Figure 2020-2030 North America Valsartan Market Size and CAGR
- Figure 2020-2030 North America Valsartan Market Volume and CAGR
- Table 2020-2030 North America Valsartan Demand List by Application
- Table 2020-2025 North America Valsartan Key Players Sales List
- Table 2020-2025 North America Valsartan Key Players Market Share List
- Table 2020-2030 North America Valsartan Demand List by Type
- Table 2020-2025 North America Valsartan Price List by Type
- Table 2020-2030 United States Valsartan Market Size and Market Volume List
- Table 2020-2030 United States Valsartan Import & Export List
- Table 2020-2030 Canada Valsartan Market Size and Market Volume List
- Table 2020-2030 Canada Valsartan Import & Export List
- Table 2020-2030 Mexico Valsartan Market Size and Market Volume List
- Table 2020-2030 Mexico Valsartan Import & Export List
- Table 2020-2030 South America Valsartan Market Size and Market Volume List
- Figure 2020-2030 South America Valsartan Market Size and CAGR
- Figure 2020-2030 South America Valsartan Market Volume and CAGR
- Table 2020-2030 South America Valsartan Demand List by Application
- Table 2020-2025 South America Valsartan Key Players Sales List
- Table 2020-2025 South America Valsartan Key Players Market Share List
- Table 2020-2030 South America Valsartan Demand List by Type
- Table 2020-2025 South America Valsartan Price List by Type
- Table 2020-2030 Brazil Valsartan Market Size and Market Volume List
- Table 2020-2030 Brazil Valsartan Import & Export List
- Table 2020-2030 Argentina Valsartan Market Size and Market Volume List
- Table 2020-2030 Argentina Valsartan Import & Export List
- Table 2020-2030 Chile Valsartan Market Size and Market Volume List
- Table 2020-2030 Chile Valsartan Import & Export List
- Table 2020-2030 Peru Valsartan Market Size and Market Volume List
- Table 2020-2030 Peru Valsartan Import & Export List
- Table 2020-2030 Asia & Pacific Valsartan Market Size and Market Volume List
- Figure 2020-2030 Asia & Pacific Valsartan Market Size and CAGR
- Figure 2020-2030 Asia & Pacific Valsartan Market Volume and CAGR
- Table 2020-2030 Asia & Pacific Valsartan Demand List by Application
- Table 2020-2025 Asia & Pacific Valsartan Key Players Sales List
- Table 2020-2025 Asia & Pacific Valsartan Key Players Market Share List
- Table 2020-2030 Asia & Pacific Valsartan Demand List by Type
- Table 2020-2025 Asia & Pacific Valsartan Price List by Type
- Table 2020-2030 China Valsartan Market Size and Market Volume List
- Table 2020-2030 China Valsartan Import & Export List
- Table 2020-2030 India Valsartan Market Size and Market Volume List
- Table 2020-2030 India Valsartan Import & Export List
- Table 2020-2030 Japan Valsartan Market Size and Market Volume List
- Table 2020-2030 Japan Valsartan Import & Export List
- Table 2020-2030 South Korea Valsartan Market Size and Market Volume List
- Table 2020-2030 South Korea Valsartan Import & Export List
- Table 2020-2030 Southeast Asia Valsartan Market Size List
- Table 2020-2030 Southeast Asia Valsartan Market Volume List
- Table 2020-2030 Southeast Asia Valsartan Import List
- Table 2020-2030 Southeast Asia Valsartan Export List
- Table 2020-2030 Australia Valsartan Market Size and Market Volume List
- Table 2020-2030 Australia Valsartan Import & Export List
- Table 2020-2030 Europe Valsartan Market Size and Market Volume List
- Figure 2020-2030 Europe Valsartan Market Size and CAGR
- Figure 2020-2030 Europe Valsartan Market Volume and CAGR
- Table 2020-2030 Europe Valsartan Demand List by Application
- Table 2020-2025 Europe Valsartan Key Players Sales List
- Table 2020-2025 Europe Valsartan Key Players Market Share List
- Table 2020-2030 Europe Valsartan Demand List by Type
- Table 2020-2025 Europe Valsartan Price List by Type
- Table 2020-2030 Germany Valsartan Market Size and Market Volume List
- Table 2020-2030 Germany Valsartan Import & Export List
- Table 2020-2030 France Valsartan Market Size and Market Volume List
- Table 2020-2030 France Valsartan Import & Export List
- Table 2020-2030 United Kingdom Valsartan Market Size and Market Volume List
- Table 2020-2030 United Kingdom Valsartan Import & Export List
- Table 2020-2030 Italy Valsartan Market Size and Market Volume List
- Table 2020-2030 Italy Valsartan Import & Export List
- Table 2020-2030 Spain Valsartan Market Size and Market Volume List
- Table 2020-2030 Spain Valsartan Import & Export List
- Table 2020-2030 Belgium Valsartan Market Size and Market Volume List
- Table 2020-2030 Belgium Valsartan Import & Export List
- Table 2020-2030 Netherlands Valsartan Market Size and Market Volume List
- Table 2020-2030 Netherlands Valsartan Import & Export List
- Table 2020-2030 Austria Valsartan Market Size and Market Volume List
- Table 2020-2030 Austria Valsartan Import & Export List
- Table 2020-2030 Poland Valsartan Market Size and Market Volume List
- Table 2020-2030 Poland Valsartan Import & Export List
- Table 2020-2030 Russia Valsartan Market Size and Market Volume List
- Table 2020-2030 Russia Valsartan Import & Export List
- Table 2020-2030 MEA Valsartan Market Size and Market Volume List
- Figure 2020-2030 MEA Valsartan Market Size and CAGR
- Figure 2020-2030 MEA Valsartan Market Volume and CAGR
- Table 2020-2030 MEA Valsartan Demand List by Application
- Table 2020-2025 MEA Valsartan Key Players Sales List
- Table 2020-2025 MEA Valsartan Key Players Market Share List
- Table 2020-2030 MEA Valsartan Demand List by Type
- Table 2020-2025 MEA Valsartan Price List by Type
- Table 2020-2030 Egypt Valsartan Market Size and Market Volume List
- Table 2020-2030 Egypt Valsartan Import & Export List
- Table 2020-2030 Israel Valsartan Market Size and Market Volume List
- Table 2020-2030 Israel Valsartan Import & Export List
- Table 2020-2030 South Africa Valsartan Market Size and Market Volume List
- Table 2020-2030 South Africa Valsartan Import & Export List
- Table 2020-2030 Gulf Cooperation Council Countries Valsartan Market Size and Market Volume List
- Table 2020-2030 Gulf Cooperation Council Countries Valsartan Import & Export List
- Table 2020-2030 Turkey Valsartan Market Size and Market Volume List
- Table 2020-2030 Turkey Valsartan Import & Export List
- Table 2020-2025 Global Valsartan Market Size List by Region
- Table 2020-2025 Global Valsartan Market Size Share List by Region
- Table 2020-2025 Global Valsartan Market Volume List by Region
- Table 2020-2025 Global Valsartan Market Volume Share List by Region
- Table 2020-2025 Global Valsartan Demand List by Application
- Table 2020-2025 Global Valsartan Demand Market Share List by Application
- Table 2020-2025 Global Valsartan Key Vendors Sales List
- Table 2020-2025 Global Valsartan Key Vendors Sales Share List
- Figure 2020-2025 Global Valsartan Market Volume and Growth Rate
- Table 2020-2025 Global Valsartan Key Vendors Revenue List
- Figure 2020-2025 Global Valsartan Market Size and Growth Rate
- Table 2020-2025 Global Valsartan Key Vendors Revenue Share List
- Table 2020-2025 Global Valsartan Demand List by Type
- Table 2020-2025 Global Valsartan Demand Market Share List by Type
- Table 2020-2025 Regional Valsartan Price List
- Table 2025-2030 Global Valsartan Market Size List by Region
- Table 2025-2030 Global Valsartan Market Size Share List by Region
- Table 2025-2030 Global Valsartan Market Volume List by Region
- Table 2025-2030 Global Valsartan Market Volume Share List by Region
- Table 2025-2030 Global Valsartan Demand List by Application
- Table 2025-2030 Global Valsartan Demand Market Share List by Application
- Table 2025-2030 Global Valsartan Key Vendors Sales List
- Table 2025-2030 Global Valsartan Key Vendors Sales Share List
- Figure 2025-2030 Global Valsartan Market Volume and Growth Rate
- Table 2025-2030 Global Valsartan Key Vendors Revenue List
- Figure 2025-2030 Global Valsartan Market Size and Growth Rate
- Table 2025-2030 Global Valsartan Key Vendors Revenue Share List
- Table 2025-2030 Global Valsartan Demand List by Type
- Table 2025-2030 Global Valsartan Demand Market Share List by Type
- Table 2025-2030 Valsartan Regional Price List
- Table Novartis Information
- Table SWOT Analysis of Novartis
- Table 2020-2025 Novartis Valsartan Sale Volume Price Cost Revenue
- Figure 2020-2025 Novartis Valsartan Sale Volume and Growth Rate
- Figure 2020-2025 Novartis Valsartan Market Share
- Table Mylan Information
- Table SWOT Analysis of Mylan
- Table 2020-2025 Mylan Valsartan Sale Volume Price Cost Revenue
- Figure 2020-2025 Mylan Valsartan Sale Volume and Growth Rate
- Figure 2020-2025 Mylan Valsartan Market Share
- Table Aurobindo Pharma Information
- Table SWOT Analysis of Aurobindo Pharma
- Table 2020-2025 Aurobindo Pharma Valsartan Sale Volume Price Cost Revenue
- Figure 2020-2025 Aurobindo Pharma Valsartan Sale Volume and Growth Rate
- Figure 2020-2025 Aurobindo Pharma Valsartan Market Share
- Table Lupin Pharmaceuticals Information
- Table SWOT Analysis of Lupin Pharmaceuticals
- Table 2020-2025 Lupin Pharmaceuticals Valsartan Sale Volume Price Cost Revenue
- Figure 2020-2025 Lupin Pharmaceuticals Valsartan Sale Volume and Growth Rate
- Figure 2020-2025 Lupin Pharmaceuticals Valsartan Market Share
- Table Alembic Pharmaceuticals Information
- Table SWOT Analysis of Alembic Pharmaceuticals
- Table 2020-2025 Alembic Pharmaceuticals Valsartan Sale Volume Price Cost Revenue
- Figure 2020-2025 Alembic Pharmaceuticals Valsartan Sale Volume and Growth Rate
- Figure 2020-2025 Alembic Pharmaceuticals Valsartan Market Share
- Table Zhejiang Tianyu Information
- Table SWOT Analysis of Zhejiang Tianyu
- Table 2020-2025 Zhejiang Tianyu Valsartan Sale Volume Price Cost Revenue
- Figure 2020-2025 Zhejiang Tianyu Valsartan Sale Volume and Growth Rate
- Figure 2020-2025 Zhejiang Tianyu Valsartan Market Share
- Table Zhejiang Huahai Information
- Table SWOT Analysis of Zhejiang Huahai
- Table 2020-2025 Zhejiang Huahai Valsartan Sale Volume Price Cost Revenue
- Figure 2020-2025 Zhejiang Huahai Valsartan Sale Volume and Growth Rate
- Figure 2020-2025 Zhejiang Huahai Valsartan Market Share
- Table Changzhou Siyao Information
- Table SWOT Analysis of Changzhou Siyao
- Table 2020-2025 Changzhou Siyao Valsartan Sale Volume Price Cost Revenue
- Figure 2020-2025 Changzhou Siyao Valsartan Sale Volume and Growth Rate
- Figure 2020-2025 Changzhou Siyao Valsartan Market Share
- Table Le Pu Hengyuan Information
- Table SWOT Analysis of Le Pu Hengyuan
- Table 2020-2025 Le Pu Hengyuan Valsartan Sale Volume Price Cost Revenue
- Figure 2020-2025 Le Pu Hengyuan Valsartan Sale Volume and Growth Rate
- Figure 2020-2025 Le Pu Hengyuan Valsartan Market Share
- Table Livzon Pharmaceutical Information
- Table SWOT Analysis of Livzon Pharmaceutical
- Table 2020-2025 Livzon Pharmaceutical Valsartan Sale Volume Price Cost Revenue
- Figure 2020-2025 Livzon Pharmaceutical Valsartan Sale Volume and Growth Rate
- Figure 2020-2025 Livzon Pharmaceutical Valsartan Market Share
- Table Tianda Pharmaceuticals Information
- Table SWOT Analysis of Tianda Pharmaceuticals
- Table 2020-2025 Tianda Pharmaceuticals Valsartan Sale Volume Price Cost Revenue
- Figure 2020-2025 Tianda Pharmaceuticals Valsartan Sale Volume and Growth Rate
- Figure 2020-2025 Tianda Pharmaceuticals Valsartan Market Share
- Table Aomei Pharmaceutical Information
- Table SWOT Analysis of Aomei Pharmaceutical
- Table 2020-2025 Aomei Pharmaceutical Valsartan Sale Volume Price Cost Revenue
- Figure 2020-2025 Aomei Pharmaceutical Valsartan Sale Volume and Growth Rate
- Figure 2020-2025 Aomei Pharmaceutical Valsartan Market Share
- Table Yung Shin Pharm Information
- Table SWOT Analysis of Yung Shin Pharm
- Table 2020-2025 Yung Shin Pharm Valsartan Sale Volume Price Cost Revenue
- Figure 2020-2025 Yung Shin Pharm Valsartan Sale Volume and Growth Rate
- Figure 2020-2025 Yung Shin Pharm Valsartan Market Share
- ......
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
